No Data
When will Hunan Nucien Pharmaceutical Co., Ltd. emerge from the shadow of losses after the termination and delay of core Innovative Drugs projects?
① Due to the high difficulty and slow progress of research and development, Hunan Nucien Pharmaceutical Co., Ltd. has terminated the development of the paramivir powder inhalation project. Additionally, due to stricter approval processes, the paramivir inhalation solution project will be postponed for two years. ② In the face of competition for paramivir injection, the adjustment of new drug projects will bring new uncertainties to the development of Hunan Nucien Pharmaceutical Co., Ltd.
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): Plans to temporarily use up to 0.1 billion yuan of idle raised funds to supplement working capital.
Glory Financial reported on December 11 that Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that the company intends to temporarily use no more than 100 million yuan (including the principal) of idle raised funds to supplement working capital, which is limited to the company's business expansion, daily operations, and other production activities related to the main business.
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): Plans to adjust the expected completion time of the "Innovative Drugs Research and Development Project" for the "Peramivir Inhalation Solution" project.
On December 11, Glonghui reported that Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that the company intends to adjust the expected completion date of the fundraising investment project "Innovative Drugs Research and Development Project" for the "Peramivir Inhalation Solution" project, under the premise that there are no changes to the project implementation entity, implementation method, and use of raised funds, with the scheduled usable status date set for December 31, 2026.
Paramevir's market share is being eroded by multiple parties, and price reductions are difficult to save the performance of hunan nucien pharmaceutical co., ltd. | Earnings conference
① In order to cope with market competition, hunan nucien pharmaceutical co., ltd. has reduced the price of its core product, peramivir; however, this move has not reversed the significant decline in the company's revenue and net income. ② hunan nucien pharmaceutical co., ltd. revealed that it has established a large customer department specifically for the development of the out-of-hospital market for products such as oseltamivir dry suspension.
Nanxin Pharmaceutical: Nanxin Pharmaceutical Report for the Third Quarter of 2024
Nanxin Pharmaceutical Report for the Third Quarter of 2024
Hunan Nucien Pharmaceutical Co., Ltd. (SHSE:688189) May Have Run Too Fast Too Soon With Recent 29% Price Plummet
No Data
